Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yi Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9804-202X; OpenAlex author ID A5080195820. Sources: OpenAlex.

Their work

Papers
65 (first author 15, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
102
Papers, trials and grants by year

2013: 3 papers · 2014: 4 papers · 2015: 3 papers · 2016: 8 papers · 2017: 7 papers · 2018: 9 papers · 2019: 8 papers · 2020: 4 papers · 2021: 7 papers · 2022: none · 2023: 5 papers · 2024: 5 papers · 2025: 2 papers

Papers 50 of 65

  1. Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-025-01477-y↗
  2. The ACSS2-PPARD-BCAT1 axis synchronously regulates branched-chain amino acid metabolism and development in pancreatic cancer. Co-author DOI 10.3724/abbs.2025111↗
  3. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. Last author DOI 10.1002/mc.23645↗
  4. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. First author DOI 10.1007/s12033-023-00875-z↗
  5. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Last author DOI 10.1038/s41401-023-01199-z↗
  6. Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Co-author DOI 10.1111/cpr.13694↗
  7. IL15RA-STAT3-GPX4/ACSL3 signaling leads to ferroptosis resistance in pancreatic cancer. Co-author DOI 10.3724/abbs.2024153↗
  8. Nuclear receptor coactivator 6 (NCoA6) promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1002/cam4.6427↗
  9. Stress granules dynamics and promising functions in pancreatic cancer. First author DOI 10.1016/j.bbcan.2023.188885↗
  10. Hernandezine induces autophagic cell death in human pancreatic cancer cells via activation of the ROS/AMPK signaling pathway. Last author DOI 10.1038/s41401-022-01006-1↗
  11. SETD8 inhibits ferroptosis in pancreatic cancer by inhibiting the expression of RRAD. Co-author DOI 10.1186/s12935-023-02899-6↗
  12. PITX2 in pancreatic stellate cells promotes EMT in pancreatic cancer cells via the Wnt/β-catenin pathway. Co-author DOI 10.3724/abbs.2023118↗
  13. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Last author DOI 10.1002/ctm2.398↗
  14. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. First author DOI 10.1016/j.canlet.2020.11.023↗
  15. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.redox.2020.101807↗
  16. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Co-author DOI 10.1038/s41401-020-00584-2↗
  17. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. First author DOI 10.1093/abbs/gmab074↗
  18. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-20-0414↗
  19. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Co-author DOI 10.1186/s12935-021-02210-5↗
  20. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  21. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Last author DOI 10.1111/cpr.12816↗
  22. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317163↗
  23. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Last author PMID 32368394↗
  24. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. First author DOI 10.1016/j.canlet.2019.03.024↗
  25. ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. Co-author DOI 10.1097/mpa.0000000000001408↗
  26. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  27. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  28. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0767-4↗
  29. Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1186/s12935-019-1025-5↗
  30. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  31. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Last author PMID 31911852↗
  32. MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. Co-author DOI 10.1002/ijc.31654↗
  33. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Co-author DOI 10.1007/s00018-017-2678-7↗
  34. Role of angiogenesis in pancreatic cancer biology and therapy. Co-author DOI 10.1016/j.biopha.2018.09.136↗
  35. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. First author DOI 10.1038/onc.2017.393↗
  36. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  37. SNX6 predicts poor prognosis and contributes to the metastasis of pancreatic cancer cells via activating epithelial-mesenchymal transition. Co-author DOI 10.1093/abbs/gmy110↗
  38. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. First author DOI 10.1111/cpr.12456↗
  39. Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer. Co-author DOI 10.3748/wjg.v24.i43.4893↗
  40. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Co-author DOI 10.7150/thno.26546↗
  41. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. First author DOI 10.1016/j.canlet.2016.12.014↗
  42. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Co-author DOI 10.1038/emm.2017.255↗
  43. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Co-author DOI 10.1038/onc.2016.306↗
  44. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1541-7786.mcr-16-0296↗
  45. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  46. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. First author DOI 10.3892/or.2017.5856↗
  47. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
  48. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  49. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.bbcan.2016.09.001↗
  50. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 57 shared papers, 2013–2025 · strength 4.92
  2. Shunrong Ji · 48 shared papers, 2013–2025 · strength 4.53
  3. Xiaowu Xu · 25 shared papers, 2019–2025 · strength 3.42
  4. Wenyan Xu · 33 shared papers, 2014–2025 · strength 2.58
  5. Jin Xu · 33 shared papers, 2013–2024 · strength 2.43
  6. Qiangsheng Hu · 24 shared papers, 2016–2023 · strength 2.11
  7. Ye Zeng · 12 shared papers, 2019–2025 · strength 1.73
  8. Wensheng Liu · 18 shared papers, 2017–2021 · strength 1.71
  9. Quanxing Ni · 24 shared papers, 2014–2019 · strength 1.51
  10. Si Shi · 26 shared papers, 2013–2020 · strength 1.44
  11. Zheng Zhang · 14 shared papers, 2018–2021 · strength 1.36
  12. Qifeng Zhuo · 10 shared papers, 2020–2025 · strength 1.29
  13. Chen Liang · 18 shared papers, 2016–2020 · strength 1.13
  14. Qiqing Sun · 12 shared papers, 2018–2020 · strength 1.08
  15. Dingkong Liang · 16 shared papers, 2015–2018 · strength 0.93
  16. Mengqi Liu · 8 shared papers, 2019–2021 · strength 0.81
  17. Haifeng Hu · 4 shared papers, 2021–2024 · strength 0.68
  18. Chenjie Zhou · 3 shared papers, 2024–2025 · strength 0.64
  19. Jinfeng Xiang · 10 shared papers, 2016–2019 · strength 0.63
  20. Borui Li · 3 shared papers, 2024–2025 · strength 0.61
  21. Qingcai Meng · 8 shared papers, 2017–2020 · strength 0.60
  22. Di Wu · 3 shared papers, 2023–2025 · strength 0.59
  23. Haidi Chen · 3 shared papers, 2021–2025 · strength 0.57
  24. Liang Liu · 12 shared papers, 2013–2017 · strength 0.53
  25. Faliang Xing · 2 shared papers, 2023–2024 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.